Author Archives: admin


Hitachi and ThinkCyte to Develop an AI-driven Cell Analysis | ARC Advisory – ARC Viewpoints

Hitachi, Ltd and ThinkCyte, Inc. announced that they have entered into a collaboration focused on developing an artificial intelligence (AI)-driven cell analysis and sorting system. Hitachi and ThinkCyte are promoting collaboration with pharmaceutical companies and research institutes working in the field of regenerative medicine and cell therapy to expedite the development of the system toward commercialization.

Founded in 2016 and headquartered in Tokyo, Japan, ThinkCyte, is a biotechnology company that develops life science research, diagnostics, and treatments using integrated multidisciplinary technologies. It has been performing research and development focused on high-throughput single cell analysis and sorting technology to precisely analyze and isolate target cells. ThinkCyte has developed the Ghost Cytometry technology to achieve high-throughput and high-content single cell sorting and has been conducting collaborative research projects with multiple pharmaceutical companies and research institutes to utilize this technology in life science and medical fields.

Hitachi has been providing large-scale automated induced pluripotent stem (iPS) cell culture equipment, cell processing facilities (CPFs), manufacturing execution systems(MES), and biosafety cabinets among other products to pharmaceutical companies and research institutes, and has developed a value chain to meet a variety of customer needs in the regenerative medicine and cell therapy industry. Hitachi has also been carrying out collaborative research projects with universities, research institutes, and other companies to develop core technologies for pharmaceutical manufacturing instruments and in vitro diagnostic medical devices, prototyping for mass production, and working on manufacturing cost reduction and the development of stable and reliable instruments.

Hitachi and ThinkCyte have initiated a joint development of the AI-driven cell analysis and sorting system based on their respective technologies, expertise, and know-how. By combining ThinkCyte's high-throughput and high-content label-free single cell sorting technology and Hitachi's know-how and capability to producing stably operative instruments on a large scale, the two companies will together develop a novel reliable system to enable high-speed label-free cell isolation with high accuracy, which has been difficult to achieve with the existing cell sorting techniques, and to realize stable, low-cost and large-scale production of cells for regenerative medicine and cell therapy.

Hitachi and ThinkCyte will further advance partnerships with pharmaceutical companies and research institutes that have been developing and manufacturing regenerative medicines and cell therapy products in Japan and other countries where demand is expected to be significant, such as North America, in order to make this technology a platform for the production of regenerative medicines and cell therapy products.

The rest is here:
Hitachi and ThinkCyte to Develop an AI-driven Cell Analysis | ARC Advisory - ARC Viewpoints

Global Leukapheresis Market is Expected to Reach at a CAGR of 9.60% from 2018 to 2025 – PharmiWeb.com

A new research report published by Fior Markets with the titleGlobal Leukapheresis Market by Type (Leukapheresis Devices, Leukapheresis Disposables), Application, End-Users, and Region and Global Forecast 2018-2025.

As per the report, theglobal leukapheresis marketis expected to grow from USD 19.29 Million in 2017 to USD 41.07 Million by 2025 at a CAGR of 9.60% during the forecast period from 2018-2025. Asia Pacific is expected to dominate the market during the forecast period. Ongoing regenerative medicine research in the region, rise in the number of clinical trials and the presence of leading pharma and biotech companies in the region are some of the major factors driving the growth of the market in region.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/375981/request-sample

Prominent players operating in the market are Asahi Kasei Medical Co., Ltd, Macopharma SA, Fresenius Se & Co. KGaA, Bioivt, Haemonetics Corporation, PPA Research Group, Inc., Hemacare Corporation, Key Biologics, LLC, Terumo BCT, ALLCells, LLC, Stemexpress, LLC, Stemcell Technologies, Inc., Caltag Medsystems Limited, Zenbio, Inc, Precision for Medicine, Inc and others. Major firms are incorporating various strategies to increase their market reach. For instance, in April 2018, Fresenius Kabi expanded its production site for medical devices in Dominican Republic (U.S). This plant manufactures and exports apheresis systems for plasma and platelet collection. This new production facility has enhanced its production capabilities to meet the demand for apheresis systems.

The type segment is classified into leukapheresis devices and leukapheresis disposables. The leukapheresis disposables segment accounted for the largest market share in 2017. The increasing applications for the isolation of primary cells from blood for cell therapy research applications is estimated to drive the growth of the segment. Applications segment is divided into research applications and therapeutic applications. The research applications segment is dominating and was valued around USD 11.13 million in 2017. Growing adoption in research activities for cancer, immunology, infectious diseases, drug discovery, regenerative medicine, and cell-based therapies are contributing to the growth of the segment. End user segment is classified into blood component providers and blood centers, academic and research institutes, pharmaceutical and biotechnology companies and hospitals and transfusion centers. The blood component providers & blood centers segment is expected to grow with the highest CAGR in the forecast period. Increasing number of blood donations and rising demand for leukopaks in clinical conditions like cancer are driving the growth.

Increasing prevalence of leukemia and rise in the blood donations are boosting demand of market in forecast period. In addition, research activities including development of cell-based immunotherapies is also boosting the growth of the market. High costs of leukapheresis may restrict the growth of the market. However, innovations in R&D activities and commercialization of new products are propelling the growth of the market in forecast period.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/global-leukapheresis-market-by-type-leukapheresis-devices-leukapheresis-375981.html

About the report: The globalleukapheresis market is analysed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report: The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us Mark Stone Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Read more:
Global Leukapheresis Market is Expected to Reach at a CAGR of 9.60% from 2018 to 2025 - PharmiWeb.com

Sweet! Rice researchers 3D print blood vessels using sugar and laser – 3DPMN

Powdered sugar is the special ingredient in a Rice University recipe for mimicking the bodys intricate, branching blood vessels in lab-grown tissues. This approach to sugar 3D printed blood vessels is not entirely new: sugar has already been used in experiments with selective laser sintering and in bioprinting. In theresearch published in the journal Nature Biomedical Engineering, Rice bioengineers showed they could keep densely packed cells alive for two weeks in relatively large constructs by creating complex blood vessel networks from templates of 3D printed sugar.

One of the biggest hurdles to engineering clinically relevant tissues is packing a large tissue structure with hundreds of millions of living cells, said study lead author Ian Kinstlinger, a bioengineering graduate student in RicesBrown School of Engineering. Delivering enough oxygen and nutrients to all the cells across that large volume of tissue becomes a monumental challenge.

Kinstlinger explains that nature solved this problem through the evolution of complex vascular networks, which weave through our tissues and organs in patterns reminiscent of tree limbs. The vessels simultaneously become smaller in thickness but greater in number as they branch away from a central trunk, allowing oxygen and nutrients to be efficiently delivered to cells throughout the body.

By developing new technologies and materials to mimic naturally occurring vascular networks, were getting closer to the point that we can provide oxygen and nutrients to a sufficient number of cells to get meaningful long-term therapeutic function, Kinstlinger said.

The sugar templates were 3D-printed with an open-source, modified laser cutter in the lab of study co-author Jordan Miller, an assistant professor of bioengineering at Rice. The 3D-printing process we developed here is like making a very precise creme brulee, said Miller, whose original inspiration for the project wasan intricate dessert.

Miller said the complex, detailed structures are made possible by selective laser sintering, a 3D-printing process that fuses minute grains of powder into solid 3D objects. In contrast to more common extrusion 3D printing, where melted strands of material are deposited through a nozzle, laser sintering works by gently melting and fusing small regions in a packed bed of dry powder. Both extrusion and laser sintering build 3D shapes one 2D layer at a time, but the laser method enables the generation of structures that would otherwise be prone to collapse if extruded, he said.

There are certain architectures such as overhanging structures, branched networks and multi vascular networks which you really cant do well with extrusion printing, said Miller, who demonstrated the concept of sugar templating with a 3D extrusion printer during his postdoctoral studies at the University of Pennsylvania. Miller began work on the laser-sintering approach shortly after joining Rice in 2013.

Sugar is especially useful in creating blood vessel templates because its durable when dry, and it rapidly dissolves in water without damaging nearby cells. To make tissues, Kinstlinger uses a special blend of sugars to print templates and then fills the volume around the printed sugar network with a mixture of cells in liquid gel. The gel becomes semisolid within minutes, and the sugar is then dissolved and flushed away to leave an open passageway for nutrients and oxygen.

A major benefit of this approach is the speed at which we can generate each tissue structure, Kinstlinger said. We can create some of the largest tissue models yet demonstrated, in under five minutes.

Miller said the new study answers two important questions: What sugars can be sintered into coherent structures, and what computational algorithms can derive complex, branching architectures that mimic those found in nature?

The computational algorithm that generated the treelike vascular architectures in the study was created in collaboration withNervous System, a design studio that uses computer simulation to make unique art, jewelry and housewares that are inspired by patterns found in nature.

Were using algorithms inspired by nature to create functional networks for tissues, said Jessica Rosenkrantz, co-founder and creative director of Nervous System and a study co-author. Because our approach is algorithmic, its possible to create customized networks for different uses.

After creating tissues patterned with these computationally generated vascular architectures, the team demonstrated the seeding of endothelial cells inside the channels and focused on studying the survival and function of cells grown in the surrounding tissue, including rodent liver cells called hepatocytes. The hepatocyte experiments were conducted in collaboration with University of Washington (UW) bioengineer and study co-authorKelly Stevens, whose research group specializes in studying the delicate cells, which are notoriously difficult to maintain outside the body.

This method could be used with a much wider range of material cocktails than many other bioprinting technologies, Stevens said. This makes it incredibly versatile.

Miller said, We showed that perfusion through 3D vascular networks allows us to sustain these large liverlike tissues. While there are still long-standing challenges associated with maintaining hepatocyte function, the ability to both generate large volumes of tissue and sustain the cells in those volumes for sufficient time to assess their function is an exciting step forward.

Stevens is an assistant professor of bioengineering in the UW College of Engineering, assistant professor of pathology in the UW School of Medicine and an investigator at theUW MedicineInstitute for Stem Cell and Regenerative Medicine.

Additional authors include Gisele Calderon, Karen Vasquez Ruiz, David Yalacki, Palvasha Deme, Kevin Janson, Daniel Sazer and Saarang Panchavati, all of Rice; Sarah Saxton and Fredrik Johansson, both of UW; Jesse Louis-Rosenberg of Nervous System; and Karl-Dimiter Bissig of Baylor College of Medicine.

The work was supported by the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the National Institutes of Health (HL134510, DK115461, DP2HL137188, T32EB001650, HL140905) and the Cancer Prevention and Research Institute of Texas via the Texas Hepatocellular Carcinoma Consortium (CPRIT RP150587).

More:
Sweet! Rice researchers 3D print blood vessels using sugar and laser - 3DPMN

Regenerative Medicine Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2026 | Acelity LP Inc., Nuvasive…

Global Regenerative Medicine Market valued approximately USD 49.68 billion in 2018 is anticipated to grow with a healthy growth rate of more than 24.2% over the forecast period 2019-2026.

Regenerative Medicine Market describes an in-depth evaluation and professional Covid-19 Outbreak study on the present and future state of the Regenerative Medicine market across the globe, including valuable facts and figures. Regenerative Medicine Market provides information regarding the emerging opportunities in the market & the market drivers, trends & upcoming technologies that will boost these growth trends. The report provides a comprehensive overview including Definitions, Scope, Application, Production and CAGR (%) Comparison, Segmentation by Type, Share, Revenue Status and Outlook, Capacity, Consumption, Market Drivers, Production Status and Outlook and Opportunities, Export, Import, Emerging Markets/Countries Growth Rate. The report presents a 360-degree overview of the competitive landscape of the industries. The Regenerative Medicine market report assesses the key regions (countries) promising a huge market share for the forecast period.

Top Key players of Regenerative Medicine Market Covered In The Report: Acelity L.P. Inc. Nuvasive Inc. Vericel Corporation Osiris Therapeutics Inc. Stryker Corporation Medtronic PLC Key Market Segmentation of Regenerative Medicine:

By Technology:

Stem Cell Therapy Biomaterial Tissue Engineering Others

By Application:

Bone Graft Substitutes Osteoarticular Diseases Dermatology Cardiovascular Central Nervous System Others

The Regenerative Medicine report gives detail complete examination to territorial sections that covered The USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, and Rest of World in Global Outlook Report with Regenerative Medicine Market definitions, characterizations, delivering reports, cost structures, advancement strategies, and plans. The results and information are top notches in the Regenerative Medicine report utilizing outlines, diagrams, pie graphs, and other pictorial portrayals concerning its Current Trends, Dynamics, and Regenerative Medicine Business Scope, Key Statistics and CAGR Analysis of top key players.

Buy Full Report Now @ https://www.qurateresearch.com/report/buy/HnM/global-regenerative-medicine-market/QBI-BRC-HnM-435840/

(A free report data (as a form of Excel Datasheet) will also be provided upon request along with a new purchase.)

Key Highlights from Regenerative Medicine Market Study:

Income and Sales Estimation Historical Revenue and deals volume is displayed and supports information is triangulated with best down and base up ways to deal with figure finish market measure and to estimate conjecture numbers for key areas shrouded in the Regenerative Medicine report alongside arranged and very much perceived Types and end-utilize industry. Moreover, macroeconomic factor and administrative procedures are discovered explanation in Regenerative Medicine industry advancement and perceptive examination.

Assembling Analysis The Regenerative Medicine report is presently broke down concerning different types and applications. The Regenerative Medicine market gives a section featuring the assembling procedure examination approved by means of essential data gathered through Industry specialists and Key authorities of profiled organizations.

Competition Analysis Regenerative Medicine Leading players have been considered relying upon their organization profile, item portfolio, limit, item/benefit value, deals, and cost/benefit.

Demand and Supply and Effectiveness Regenerative Medicine report moreover gives support, Production, Consumption and (Export and Import).

Which prime data figures are included in the report? -Market size (Last few years, current and expected) -Market share analysis as per different companies) -Market forecast) -Demand) -Price Analysis) -Market Contributions (Size, Share as per regional boundaries)

Who all can be benefitted out of this report? -Market Investigators -Teams, departments, and companies -Competitive organizations -Individual professionals -Vendors, Buyers, Suppliers -Others

What are the crucial aspects incorporated in the report? -Industry Value Chain -Consumption Data -Market Size Expansion -Key Economic Indicators

Strategic Points Covered in TOC:

Chapter 1: Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Regenerative Medicine market.

Chapter 2: Evaluating the leading manufacturers of the global Regenerative Medicine market which consists of its revenue, sales, and price of the products.

Chapter 3: Displaying the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4: Presenting global Regenerative Medicine market by regions, market share and with revenue and sales for the projected period.

Chapter 5, 6, 7, 8 and 9: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Contact Us:

Web:www.qurateresearch.com E-mail:[emailprotected] Ph: US +13393375221

Note: In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Visit link:
Regenerative Medicine Market 2020 | Covid19 Impact Analysis | Business Outlook, Growth, Revenue, Trends and Forecasts 2026 | Acelity LP Inc., Nuvasive...

Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D., Ph.D., Internationally Recognized for His Seminal Contributions…

GOLDEN, Colo.--(BUSINESS WIRE)--Reven Holdings, Inc. (Reven), a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, viral illnessesincluding COVID-19and inflammatory disorders, today announced the appointment of Dr. Fatih M. Uckun as its Chief Medical Officer and Chief Scientific Officer.

In his new position at Reven, Dr. Uckun will provide executive oversight for Revens global Research & Development and clinical programs. In addition, Dr. Uckun will contribute medical-scientific leadership and direction for Revens basic and translational research activities, R&D and clinical development programs in cancer, transplantation immunology, sepsis, metabolic disorders, inflammatory disorders, and the acute respiratory distress syndrome (ARDS) in patients with sepsis, including COVID-19 patients with viral sepsis.

Dr. Uckun stated, It is an exceptionally exciting time to join Reven to support a global registration strategy for its unique RJX platform. The components of RJX exhibited very promising activity in clinical studies involving ARDS patients and non-clinical studies in animal models of ARDS. The published data from these clinical, and recent non-clinical, studies confirming its unique mechanism of action, provide the medical-scientific rationale for Revens clinical development strategy for RJX. The clinical study in COVID-19 patients is a logical next step. I very much look forward to working with the talented and experienced leadership team of Reven and our collaborators. The goal is to diligently advance the RJX clinical trial program with the vision of developing RJX-based new treatments for COVID-19 patients, as well as patients with difficult-to-treat forms of cancer and inflammatory disorders who are in urgent need for therapeutic innovations.

As we move forward with our planned clinical trial of Rejuveinix (RJX) for treatment of COVID-19, Dr. Uckuns decades of drug development experience will be critical in successful execution and the establishment of effective collaborations with other stakeholders, said Peter Lange, Chief Executive Officer of Reven. Dr. Uckun embodies Revens core values: dedication to patients, passion for science, and excellence in execution. I am delighted to have the opportunity to welcome Dr. Uckun as part of Revens leadership team.

About Dr. Uckun

Dr. Uckun is an elected Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations. He received numerous awards for his work on monoclonal antibodies, recombinant cytokines and fusion proteins, radiation sensitizers, kinase inhibitors and targeted therapeutics for difficult-to-treat cancers, including the Stohlman Memorial Award of the Leukemia Society of America, the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and National Institutes of Health grant review/special emphasis panels.

Dr. Uckun earned his doctoral degrees at the University of Heidelberg, Germany, where he also served as an active member of the autologous bone marrow transplant and peripheral stem cell transplant clinical research teams of the Tumor Center. Dr. Uckun completed his residency training in pediatrics, clinical fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology and microbiology at the University of Minnesota. Dr. Uckun has more than thirty years of professional experience in developmental therapeutics with a special emphasis on targeted therapeutics/precision medicines and biopharmaceuticals. He has published more than 500 peer-reviewed papers, authored numerous review articles and book chapters, and is an inventor on numerous patents.

For eleven years, Dr. Uckun worked as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. At the Keck School of Medicine of the University of Southern California, he was a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative for six years. From 2012 to 2015, Dr. Uckun served as chair of the Biotargeting Working Group and a Member of the Coordination and Governance Committee of the National Cancer Institute Alliance for Nanotechnology in Cancer.

Dr. Uckun has held executive positions in multiple biotechnology companies and has extensive regulatory experience. Prior to joining Reven, Dr. Uckun served as Vice President of Scientific Solutions at Worldwide Clinical Trials, Chief Medical Officer of Oncotelic and Mateon Therapeutics, Head of Immuno-Oncology at Ares Pharmaceuticals, and as Executive Medical Director and Strategy Lead in Global Oncology and Hematology at Syneos Health. Previously, he was Vice President of Research and Clinical Development at Nantkwest, and Chief Scientific Officer of both Jupiter Research Institute and Paradigm Pharmaceuticals. Dr. Uckun is a former Vice Chair of the New Agents Committee as well as a Member of the Leukemia Steering Committee of the Childrens Cancer Study Group, an NCI-funded cooperative clinical trials consortium that coordinated pediatric and adolescent/young adult leukemia trials at 120 institutions in the U.S., Canada, Australia and Europe.

Dr. Uckun has deep knowledge and experience in the treatment of infectious diseases and their complications. In particular, he has extensive experience in viral, fungal, and bacterial infections of immunocompromised hosts, septic shock, ARDS, systemic capillary leak syndrome and cytokine release syndrome (CRS). He served as the Principal Investigator of a virus neutralizer project funded by the Defense Advanced Research Projects Agency (DARPA) as part of its unconventional countermeasures program. Dr. Uckun directed several federally funded virology/innate immunity projects and published numerous peer-reviewed papers on RNA viruses and anti-viral agents.

About Rejuveinix (RJX)

RJX is an intravenous (IV) formulation of known physiologically compatible compounds that is being developed for more effective supportive therapy of patients with sepsis, including COVID-19 patients with viral sepsis and acute respiratory distress syndrome (ARDS). The RJX formulation is a solution of buffered acid products, electrolyte components, and vitamins, including ascorbic acid, cyanocobalamin, thiamine hydrochloride, riboflavin 5 phosphate, niacinamide, pyridoxine hydrochloride, and calcium d-pantothenate, and magnesium sulfate heptahydrate, a mineral with a negative oxidation-reduction potential. The components of RJX exhibited promising activity in clinical studies involving ARDS patients and/or non-clinical studies in animal models of ARDS. The published data from these clinical and non-clinical studies provided the medical-scientific rationale for Revens clinical development strategy for RJX and a clinical study in COVID-19 patients. The clinical tolerability of RJX was confirmed in a recently completed double blind, placebo-controlled Phase 1 dose-escalation study in healthy volunteers (ClinicalTrials.gov Identifier: NCT03680105).

About Reven Holdings, Inc.

Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado-based operating company Reven, LLC, is a biopharmaceutical company. Revens vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

Revens Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as may, on-track, expect, anticipate hope, vision, optimism, design, exciting, promising, will, conviction, estimate, intend, believe and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the companys product candidates and the potential use of the companys product candidates to treat various disease indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing market competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates, and unexpected litigation or other disputes. These risks are not exhaustive; the company faces known and unknown risks, including the risk factors described in the companys periodic SEC filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information regarding future events, or otherwise.

Continue reading here:
Reven Announces the Appointment of Eminent Physician-Scientist Fatih M. Uckun, M.D., Ph.D., Internationally Recognized for His Seminal Contributions...

Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2025 UpMarketResearch – 3rd Watch News

Regenerative Medicine Products Market Forecast 2020-2026

The Global Regenerative Medicine Products Market research report provides and in-depth analysis on industry- and economy-wide database for business management that could potentially offer development and profitability for players in this market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It offers critical information pertaining to the current and future growth of the market. It focuses on technologies, volume, and materials in, and in-depth analysis of the market. The study has a section dedicated for profiling key companies in the market along with the market shares they hold.

The report consists of trends that are anticipated to impact the growth of the Regenerative Medicine Products Market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Get a PDF Copy of the Sample Report for free @ https://www.upmarketresearch.com/home/requested_sample/107455

The Report Covers the Following Companies: Acelity DePuy Synthes Medtronic ZimmerBiomet Stryker MiMedx Group Organogenesis UniQure Cellular Dynamics International Osiris Therapeutics Vcanbio Gamida Cell Golden Meditech Cytori Therapeutics Celgene Vericel Corporation Guanhao Biotech Mesoblast Stemcell Technologes Bellicum Pharmaceuticals

By Types: Cell Therapy Tissue Engineering Biomaterial Others

By Applications: Dermatology Cardiovascular CNS Orthopedic Others

Furthermore, the report includes growth rate of the global market, consumption tables, facts, figures, and statistics of key segments.

By Regions:

Grab Your Report at an Impressive Discount! Please click here @ https://www.upmarketresearch.com/home/request_for_discount/107455

Years Considered to Estimate the Market Size: History Year: 2015-2019 Base Year: 2019 Estimated Year: 2020 Forecast Year: 2020-2026

Important Facts about Regenerative Medicine Products Market Report:

What Our Report Offers:

Make an Inquiry of This Report @ https://www.upmarketresearch.com/home/enquiry_before_buying/107455

About UpMarketResearch: Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearch Name Alex Mathews Email [emailprotected] Organization UpMarketResearch Address 500 East E Street, Ontario, CA 91764, United States.

View post:
Regenerative Medicine Products Market, Share, Growth, Trends And Forecast To 2025 UpMarketResearch - 3rd Watch News

Global and Country Specific CRISPR And CRISPR Associated Genes Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and…

CRISPR And CRISPR Associated Genes Market report involves all together a different chapter on COVID 19 Impact. The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303. Download The report Copy form the webstie: https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report

The major players profiled in this report include: Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies

Market segment by type can be split into: Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics, Intellia therapeutics Inc., Cellectis, Horizon Discovery Plc, Sigma Aldrich, Precision Biosciences, Genscript, Sangamo Biosciences Inc., Lonza Group Limited, Integrated DNA Technologies, New England Biolabs, Origene Technologies, Market segment by Regions/Countries this report covers, North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, Market segment by Type the product can be split into, Genome Editing, Genetic engineering, GRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

Market segment by the application can be split into: Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

DOWNLOAD FREE SAMPLE REPORT@: https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report#download_report

As government of different regions have already announced total lockdown and temporarily shutdown of industries, the overall production process being adversely affected; thus, hinder the overall CRISPR And CRISPR Associated Genes globally. This report on CRISPR And CRISPR Associated Genes provides the analysis on impact on Covid-19 on various business segments and country markets. The report also showcases market trends and forecast to 2027, factoring the impact of COVID-19 situation.

CRISPR And CRISPR Associated Genes Market report provide an in-depth understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, and opportunities in the market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of last three years. Moreover, the report also offers a 360 outlook of the market through the competitive landscape of the global industry player and helps the companies to garner CRISPR And CRISPR Associated Genes Market revenue by understanding the strategic growth approaches.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of CRISPR And CRISPR Associated Genes Market Report 2020 (Coronavirus Impact Analysis on CRISPR And CRISPR Associated Genes Market)

Report provides industry analysis, important insights, and a competitive and useful advantage to the pursuers. The report analyzes different segments and offers the current and future prospects of each segment. Furthermore, this research report contains an in depth analysis of the top players with data such as product specification, company profiles and product picture, sales area, and base of manufacturing in the global CRISPR And CRISPR Associated Genes market. The impact on the supply and demand of the raw materials, due to the COVID-19 is also analyzed in the global CRISPR And CRISPR Associated Genes market.

Additionally, report consists of product life cycle, which discus about the current stage of product. Further, it adds manufacturing cost analysis as well as complete manufacturing process involved. Report also adds supply chain analysis to ensure complete data of market.

Objectives of CRISPR And CRISPR Associated Genes Market Report: To justifiably share in-depth info regarding the decisive elements impacting the increase of industry (growth capacity, chances, drivers and industry specific challenge and risks) To know the CRISPR And CRISPR Associated Genes Market by pinpointing its many sub segments To profile the important players and analyze their growth plans To endeavor the amount and value of the CRISPR And CRISPR Associated Genes Market sub-markets, depending on key regions (various vital states) To analyze the Global CRISPR And CRISPR Associated Genes Market concerning growth trends, prospects and also their participation in the entire sector To inspect and study the Global CRISPR And CRISPR Associated Genes Market size form the company, essential regions/countries, products and applications, background information and also predictions to 2027 Primary worldwide CRISPR And CRISPR Associated Genes Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans for the next coming years To examine competitive progress such as expansions, arrangements, new product launches and acquisitions on the market

Access Exclusive Free Sample Report (COVID-19 Impact Analysis Updated Edition): Click Here> Download Sample Report of CRISPR And CRISPR Associated Genes Market Report 2020 (Pandemic Impact Analysis Updated Edition May 2020)

Follow is the chapters covered in CRISPR And CRISPR Associated Genes Market: Chapter 1 CRISPR And CRISPR Associated Genes Market Overview Chapter 2 COVID 19 Impact Chapter 3 CRISPR And CRISPR Associated Genes Segment by Types (Product World) Chapter 4 Global CRISPR And CRISPR Associated Genes Segment by Application Chapter 5 Global CRISPR And CRISPR Associated Genes Market by Regions (2015-2027) Chapter 6 Global CRISPR And CRISPR Associated Genes Market Competition by Manufacturers Chapter 7 Company (Top Players) Profiles and Key Data Chapter 8 Global CRISPR And CRISPR Associated Genes Revenue by Regions (2015-2020) Chapter 9 Global CRISPR And CRISPR Associated Genes Revenue by Types Chapter 10 Global CRISPR And CRISPR Associated Genes Market Analysis by Application Chapter 11 North America CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 12 Europe CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 13 Asia Pacific CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 14 South America CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 15 Middle East & Africa CRISPR And CRISPR Associated Genes Market Development Status and Outlook Chapter 16 CRISPR And CRISPR Associated Genes Manufacturing Cost Analysis Chapter 17 Marketing Strategy Analysis, Distributors/ Traders Chapter 18 Global CRISPR And CRISPR Associated Genes Market Forecast (2020-2027) Chapter 19 Research Findings and Conclusion Get detailed TOC for CRISPR And CRISPR Associated Genes Market Report @ https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report#table_of_contents.

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on to share your research requirements.nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/pharma-%26-healthcare/crispr-and-crispr-associated-genes-market-report

Continued here:
Global and Country Specific CRISPR And CRISPR Associated Genes Market Report 2020 Forecast, Opportunities and Strategies To 2027: COVID 19 Impact and...

Global Tooth Regeneration Market : Industry Analysis and Forecast (2020-2027)-by Type, Application, Population Demographics and Region. – Morning Tick

Global Tooth Regeneration Market was valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 6.5% during a forecast period 2020-2027.

Global Tooth Regeneration Market, By Regions

Market Dynamics

The Research Report gives a comprehensive account of the drivers and restraints in the tooth regeneration. Somatic stem cells are composed and reprogrammed to induced pluripotent stem cells which can be placed in the dental lamina directly or placed in an absorbable biopolymer in the shape of the new tooth, which is a main source of the novel bioengineered teeth. Tooth replacement therapy is pondered to be a greatly attractive concept for the next generation bioengineered organ replacement.The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

The global tooth regeneration market is mainly compelled by the high occurrence of dental problems with the new research and development activities. According to WHO, the Global Burden of Disease Study 2017 estimated that oral diseases affect close to 3.5 billion people worldwide, with caries of permanent teeth being the most common condition. Globally, it is likely that 2.3 billion people suffer from caries of permanent teeth and more than 530 million children suffer from caries of primary teeth. Additionally, positive refund policies for instance coverage of Medicaid insurance for dental loss treatment and emergence of new technologies like laser tooth generation techniques are projected to enhance the global tooth generation market throughout the estimated period.

Request For View Sample Report Page :@ https://www.maximizemarketresearch.com/request-sample/55424/

Different researches are carried out by several academies and corporations to understand the possibility of stem cell-based regenerative medicines tooth regeneration. Though stem cell is the protuberant technology in research for tooth regeneration, several organizations are also leveraging laser, drug, and gel as mediums to regenerate teeth. For example, the Wyss Institute at Harvard University is engaged in research related to tooth regeneration using lasers. Tooth generation using stem cells is now under research through the globe. There are some key stem cells on which research are carried out such as stem cells from human exfoliated deciduous teeth (SHEDs), dental pulp stem cells, dental follicle progenitor cells (DFPCs), periodontal ligament stem cells (PDLSCs), and stem cells from apical papilla (SCAPs). A 2009 nationwide survey by the Nova South-eastern University in the U.S. publicized that around 96% of dentists expect stem cell regeneration to lead the future of the dentistry industry. However, occurrence rates are growing in low and middle-income countries. Though, some factors like the preference for endodontic treatment over tooth regeneration products in key dental surgeries and local inflammatory activity, which results in chronic complications to dental replacements, is anticipated to hamper the market throughout the forecast period.

Global Tooth Regeneration Market Segment analysis

Based on population demographics, the geriatric segment is expected to grow at a CAGR of XX% during the forecast period. According to NIH, the geriatric population has an average 18.9 remaining teeth. About 23% of the geriatric population has no teeth, making a positive market situation for manufacturing companies. The above 18 million dental procedures are anticipated to be carried out amongst the geriatric population between 2019 and 2027. Commercialization of tooth regeneration is expected to create lucrative market opportunities for industry players. Based on Type, the dentin segment accounted for a projecting share of the global tooth regeneration market in 2019, owing to the growing occurrence of dental surgery and the uprising demand for tooth regeneration in cosmetic surgery, particularly from developing economies like India, China, and Brazil.

Global Tooth Regeneration Market Regional analysis

Do Inquiry Before Purchasing Report Here: @ https://www.maximizemarketresearch.com/inquiry-before-buying/55424/

The Asia Pacific is projected to dominate the global tooth regeneration market throughout the forecast period. Tooth regeneration addressable market is likely to be highest in the Asia Pacific, with China and India located as the major growth engines. The occurrence of tooth regeneration is projected to capture this market. Also, the number of dental procedures is anticipated to grow at the highest CAGR of ~10.8% in the Asia Pacific between 2019 and 2027. Besides, the growing incidence of dental cavities & periodontics, particularly in emerging countries like China and India has led to the rising demand for orthopedic & dental surgery. North America and Europe are estimated to collectively account for the major share of global procedures during the forecast period.

Key Developments

In June 2018, Datum Dental Ltd., the prominent provider of OSSIX brand innovative solutions for bone and tissue regeneration for dentistry, announced clearances for OSSIX Bone with Health Canada and CE Mark approval in Europe. OSSIX Bone received FDA clearance in July 2017 and was launched commercially in the USA. In April 2018, Datum Dental, the leading provider of OSSIX brand innovative solutions for bone and tissue regeneration for dentistry, announced the expansion of its global distribution network. In the USA, Dentsply Sirona Implants is now promoting the full OSSIX line.

The objective of the report is to present a comprehensive analysis of the Global Tooth Regeneration Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Tooth Regeneration Market dynamics, structure by analysing the market segments and projects the Global Tooth Regeneration Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Tooth Regeneration Market make the report investors guide. Scope of the Global Tooth Regeneration Market

Global Tooth Regeneration Market, By Type

Dentin Dental Pulp Tooth Enamel Global Tooth Regeneration Market, By Applications

Hospitals Dental Clinics Others Global Tooth Regeneration Market, By Population Demographics

Geriatric Middle-aged Adults Others Global Tooth Regeneration Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA) Key Players operating the Global Tooth Regeneration Market

Unilever Straumann Dentsply Sirona 3M Zimmer Biomet Ocata Therapeutics Integra LifeSciences Datum Dental CryoLife BioMimetic Therapeutic Cook Medical

Major Table of Contents Report

Chapter One: Tooth Regeneration Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Tooth Regeneration Market Competition, by Players

Chapter Four: Global Tooth Regeneration Market Size by Regions

Chapter Five: North America Tooth Regeneration Revenue by Countries

Chapter Six: Europe Tooth Regeneration Revenue by Countries

Chapter Seven: Asia-Pacific Tooth Regeneration Revenue by Countries

Chapter Eight: South America Tooth Regeneration Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Tooth Regeneration by Countries

Chapter Ten: Global Tooth Regeneration Market Segment by Type

Chapter Eleven: Global Tooth Regeneration Market Segment by Application

Chapter Twelve: Global Tooth Regeneration Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Tooth Regeneration Market Report at: https://www.maximizemarketresearch.com/market-report/global-tooth-regeneration-market/55424/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: Maximize Market Research Pvt. Ltd.

Email: sales@maximizemarketresearch.com

Contact: +919607065656 / +919607195908

Website: http://www.maximizemarketresearch.com

Follow this link:
Global Tooth Regeneration Market : Industry Analysis and Forecast (2020-2027)-by Type, Application, Population Demographics and Region. - Morning Tick

Clinical Laboratory Services Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2026 – 3rd Watch News

Data Bridge Market Research has recently added a concise research on the Clinical Laboratory Services Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail. The CAGR value, technological development, new product launches and Industry competitive structure is elaborated.

Clinical laboratory services marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2020 to 2027 and expected to reach USD 217,941.33 million by 2027 from USD 134,692.52 million in 2019. Rising demand for early and accurate disease diagnosis is the factors for the market growth.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-clinical-laboratory-services-market&captain

Clinical laboratory services is playing significant role to enable doctors to make appropriate clinical and diagnostic decisions across various levels of health care services. Increasing demand for diagnostic tests is augmenting the market growth as they are used for clinical diagnoses tests.

The major players covered in the report are:-

Mayo Foundation for Medical Education and Research (MFMER), Laboratory Corporation of America Holding, Quest Diagnostics Incorporated, Spectra Laboratories (A Subsidiary of Fresenius Medical Care AG & Co. KGaA), DaVita Inc., Eurofins Scientific, UNILABS, SYNLAB International GmbH, MIRACA HOLDINGS Inc., Sonic Healthcare, ACM Global Laboratories, amedes Group, LifeLabs, Alere (A Subsidiary of Abbott), Charles River, Siemens Healthineers AG, BioReference Laboratories, Inc., NeoGenomics Laboratories, Inc., KingMed Diagnostics, Genomic Health, among other players domestic and global. Clinical laboratory services market share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many business expansion and developments are also initiated by the companies worldwide which are also accelerating the growth of global clinical laboratory services market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for Clinical Laboratory Services through expanded model range.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Global Clinical Laboratory Services Market By Specialty (Clinical Chemistry Testing, Hematology Testing, Microbiology Testing, Immunology Testing, Drugs of Abuse Testing, Cytology Testing, Genetic Testing), Provider (Hospital-Based Laboratories, Independent & Reference Laboratories, Nursing and Physician Office-Based Laboratories), Application (Bioanalytical & Lab Chemistry Services, Drug Development Related Services, Drug Discovery Related Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services, Other Clinical Laboratory Services), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Market Trends and Forecast to 2027

Rising demand of clinical laboratory services across the world is one of the prominent factors for increasing demand of clinical chemistry testing. For instance, yearly in the U.K., the usually citizen has 14 tests completed by a laboratory specialist. However in the U.S., laboratory testing is the only highest-volume medical activity and approximately 13,000 million tests are performed per year. Hence, this factor has led the patients to shift towards clinical chemistry testing because it offers a wide range of tests which are performed in the clinical laboratory testing. In the current scenario the technological advancements boost the patients reach to laboratory testing, which is becoming gradually more precise and affordable. For instance, point-of-care testing (POCT) is regularly applied in hospitals and other healthcare practices, so the patients not need to travel to the clinical laboratories for testing. The increasing use of point-of-care testing has reduced demand tests which are conventionally executed at industry laboratories.

Rising demand of early and accurate disease diagnosis across the globe is one of the prominent factors for an upsurge demand of clinical laboratory services. For instance, in 2018, World Health Organization projected that projected that an estimated 1.8 million new cases and almost 861,000 deaths occur due to colorectal cancer (CRC). This factor has increased the number of clinical laboratories around the globe as Delays in accessing cancer care are very common in the late-stage presentation, especially in lower vulnerable populations and resource settings.

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying?dbmr=global-clinical-laboratory-services-market&captain

Table of Contents-Snapshot Executive Summary Chapter 1 Industry Overview Chapter 2 Industry Competition by Manufacturers Chapter 3 Industry Production Market Share by Regions Chapter 4 Industry Consumption by Regions Chapter 5 Industry Production, Revenue, Price Trend by Type Chapter 6 Industry Analysis by Applications Chapter 7 Company Profiles and Key Figures in Industry Business Chapter 8 Industry Manufacturing Cost Analysis Chapter 9 Marketing Channel, Distributors and Customers Chapter 10 Market Dynamics Chapter 11 Industry Forecast Chapter 12 Research Findings and Conclusion Chapter 13 Methodology and Data Source

Country Level Analysis, By Provider

North America dominates the clinical laboratory services market as the U.S. is leader in clinical laboratory services. In North America due to better advancement in products and services, this region is dominating the clinical laboratory services. North America accounts higher healthcare expenditure, especially in U.S. Asia-Pacific is growing with the highest CAGR due to increase in medical tourism as well as increase in population. Numbers of companies in emerging countries are increasing due to increase in demand for disease diagnosis in clinics, hospitals and other areas. Additionally, the increasing number of healthcare expenditure and increasing number of hospitals and clinical diagnostic laboratories in China and India upsurge demand of clinical laboratory services. The Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing infectious diseases.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Read More @ https://www.databridgemarketresearch.com/reports/global-clinical-laboratory-services-market?utm_source=news&utm_campaign=Captain

Huge Investment by laboratory for Clinical Laboratory Services and New Technology Penetration

Global clinical laboratory services market also provides you with detailed market analysis for every country growth in life science industry with clinical laboratory services demand impact of technological development in laboratory services and changes in regulatory scenarios with their support for the clinical laboratory services market. The data is available for historic period 2010 to 2018.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Continue reading here:
Clinical Laboratory Services Market Data Highlighting Major Vendors, Promising Regions, Anticipated Growth Forecast To 2026 - 3rd Watch News

Stem Cell and Cancer Research Institute terminated by McMaster University – TheSpec.com

McMaster University is terminating a high-profile research institute that investigates novel stem cell and cancer therapies.

The loss of the multimillion dollar Stem Cell and Cancer Research Institute (SCC-RI) may extend to its prominent leader as questions remain about whether Mick Bhatia will stay in Hamilton. Two other researchers Kristin Hope and Karun Singh are already leaving for Toronto.

McMaster and Bhatia tell very different stories about how a university board of governors meeting on June 4 came to include the recommendation to end the nationally known institute.

My vision was to have an international presence and supremacy in stem cells, said Bhatia. McMaster, in the end, in my interpretation, really just didnt have the appetite to go in that direction.

The university claims SCC-RI has run its course because its researchers werent collaborating, which is the entire purpose of an institute.

They werent working together, said Jonathan Bramson vice-dean of research for the faculty of health sciences. We put people together because we think they will work together and achieve a situation where the sum is greater than the parts and that wasnt the case here.

Bhatia says he cant possibly compute that explanation, pointing out he has published at least one paper with every researcher at SCC-RI and the other researchers have done the same.

It doesnt make sense, he said. Its like saying the Raptors arent good at basketball.

In fact, it was collaboration that lured Bhatia to McMaster from California in 2006 in the first place. He was working toward leading a stem cell institute there when Dr. John Kelton, who was dean of the faculty of health sciences at the time, made Bhatia believe it would work better back home in Ontario.

I was completely enchanted of the idea that in Canada you could achieve that level of excellence and there was support to build something, he said. It was a great opportunity that I thought couldnt happen here in Canada and yet here it was in front of me.

The institute was set up with $10 million from Michael G. DeGroote and, over time, got another $15 million from David Braley and $24 million from the Boris family.

We were really starting from scratch, said Bhatia. There were no people working deeply in stem cell biology you had to recruit from outside because there is no pre-existing expertise, equipment or infrastructure.

At its height, SCC-RI had 13,000 square feet of state-of-the art facilities, 130 staff and millions in grants including $13 million from the Ontario Research Fund, roughly $10 million from the Canadian Foundation of Innovation and in the last fiscal year alone its scientists were awarded $3.28 million in research grants.

It had findings that were paradigm shifting for stem cell research, collaborated with biochemists which was a first for the field and took potential new cancer drugs into clinical trials.

John Kelton . was pretty visionary, said Bhatia. He was looking for areas to be truly excellent and his definition of excellence was very akin to mine ... It excited me that you could do this level of science and there was like-minded people thinking about that direction.

But at the 10-year-mark in 2016, Bhatia describes the beginning of a rift between his future vision of SCC-RI and that of McMaster. It was at the same time Kelton retired and was replaced by Dr. Paul OByrne.

We got to a point where I saw this as a Stage 1 achievement, whereas I think they were feeling this is where we needed to be and they were quite happy with it, said Bhatia. I thought we could do more.

About two years ago, funding ran out for two researchers Bhatia had recruited and trained over 10 years, and they ended up leaving McMaster. He also saw no way to recruit the senior scientists he felt he could now attract at the established institute.

By December 2019, Bhatia said he saw the writing on the wall and resigned as director of SCC-RI.

To some degree its understandable, said Bhatia. This type of science and at this level is very, very expensive. It requires an immense commitment There is a certain risk measure that comes with that.

In the wake of Bhatias resignation, McMaster spent about $8,000 on an external review which Bramson said concluded there was no collaboration.

Its a series of individuals who are operating independently, he said. Some of those individuals are quite successful which is great and they continue to operate independently but there was no value gained by having them work together.

Bramson said he doesnt know why they werent collaborating and the review didnt shed any light on that either.

Never miss the latest news from The Spectator, including up-to-date coronavirus coverage, with our email newsletters.

I cant tell you why people can or cannot work together, he said. Its their choice, they dont have to, youre not obliged to collaborate.

In fact, he says its not in a researchers nature to work together.

Scientists are mavericks, said Bramson. They are stallions, they are not trained to work together, theyre trained to work independently.

He also said this happens all the time about research institutes being terminated.

It didnt work out, I dont really see that as being a surprise, he said. Science is an experiment ... When you create an institute, you dont know how its going to shake out.

At some point between December and the board of governors meeting in June, two other principle investigators announced they were leaving.

People leave for their own reasons, said Bramson. Clearly, if they felt that they were gaining something from being part of the institute, they would have stayed.

Other principle investigators including Dr. Sheila Singh and Dr. Tobias Berg appear to be staying at McMaster and continuing their research independently.

The group was not the reason they were successful, said Bramson. Disbanding the group is not going to diminish that success. Theyre going to continue doing what theyre doing.

No principle investigators responded to The Spectators request for comment. Although Bhatia says the university made it clear to all that it was speaking on the institutes behalf. He was originally unable to speak himself but eventually got permission from McMaster.

For now, Bhatia is continuing on with his research here.

I love Canada, he said. I love McMaster.

But he added his priority is moving stem cell and cancer therapy science forward.

Well have to see how that unfolds, he said.

As for OByrnes decision to recommend terminating the institute, Bhatia says, It was the obvious decision.

Report an error

Journalistic Standards

About The Spec

Original post:
Stem Cell and Cancer Research Institute terminated by McMaster University - TheSpec.com